EX-99 2 exhibit_99-1.htm EXHIBIT 99.1 exhibit_99-1.htm


EXHIBIT 99.1


Lumenis Ltd. Reports Full Year 2012 Financial Results

Yokneam, Israel, March 28, 2013 – Lumenis Ltd., the world's largest medical laser company developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, aesthetic and ophthalmic applications, announced its financial results for the year ended December 31, 2012.

2012 Financial Highlights

 
·
Total Revenues of $248.6 million, increased by 0.7% or $1.6 million from $247.0 million in 2011.
 
·
GAAP operating income increased by 72% to $9.3 million compared to $5.4 million in 2011.
 
·
Non–GAAP operating income of $13.0 million compared to $7.6 million in 2011, up by $5.4 million (71%).
 
·
Net income on a GAAP basis for 2012 was up by $6.3 million to $7.0 million, compared to net income of $0.7 million in 2011.
 
·
Non-GAAP net income was up by $7.9 million to $9.8 million compared to $1.9 million in 2011.
 
·
Positive cash flow from operations improved to $7.0 million compared to $4.2 million in 2011.
 
·
Cash, cash equivalents and short term bank deposits as of December 31, 2012, totaled $27.1 million, compared to $38.5 million as of December 31, 2011 following repayment of $15.1 million of bank loan.
 
·
Outstanding principal bank debt was $73.9 million at year end 2012, compared to $89.0 million in 2011. Total debt net of Cash, cash equivalents and short term bank deposits as of December 31, 2012, totaled $46.8 million, compared to $50.5 million as of December 31, 2011.
 
“During 2012, we focused on improved execution, and indeed, our efforts bore fruits as exhibited in significantly higher gross margin reaching 50%, and so did our profitability and cash flow from operations," said Ms. Ozer-Armon, CEO of Lumenis. "As we continued our expansion in the emerging markets, we maintained the strong growth in China/APAC region with 24% year-over-year growth. The confidence in our products continues to build, with Lumenis’ Surgical business growing by 7% in 2012,” concluded Ms. Ozer-Armon.
 
 
 
 

 

Use of Non-GAAP Financial Information
 
In addition to reporting financial results in accordance with United States generally accepted accounting principles, or GAAP, Lumenis uses non-GAAP measures of operating income, net income and earnings per share, which consist of GAAP financial measures adjusted to exclude stock-based compensation charges in accordance with ASC Topic 718, amortization of acquired intangible assets, restructuring and related charges, legal settlements net of associated legal costs, and other non-recurring items. Lumenis’ management believes the non-GAAP financial information provided in this release is useful to investors’ understanding and assessment of Lumenis’ ongoing core operating results.  Our management regularly uses the non-GAAP measures in planning, forecasting, understanding and evaluating the business and decision making.  We believe that these financial non-GAAP measures are useful for the investor as a measure of the ongoing performance of Lumenis’ business.  The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures discussed in this press release to the most directly comparable GAAP financial measures is included with the financial statements contained in this press release.

Availability of Form 20-F
Lumenis’ annual Report on Form 20-F for the year ended December 31, 2012 is available from the Securities and Exchange Commission’s website at www.sec.gov as well as under the Investor Relations section of Lumenis’ website at www.lumenis.com.  Shareholders may receive a copy of the report free of charge upon request.

About Lumenis
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an installed base of over 80,000 systems, and a presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers.  The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: www.lumenis.com.
 
For further information contact:
Ophir Yakovian
Chief Financial Officer                                                 
Tel: +972-4-9599333
ophir.yakovian@lumenis.com         

 
 
 

 
 
                                                                                               

Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis Ltd.
 
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors,” as well in our reports on Form 6-K, filed with the Securities and Exchange Commission
 

 
 

 

LUMENIS LTD
 
CONDENSED US GAAP STATEMENT OF OPERATIONS
U.S. dollars in thousands (except per share data)
(Audited)
 
   
Year Ended December 31
 
   
2012
   
2011
 
             
Sales
           
Product
  $ 198,811     $ 199,714  
Service
    49,779       47,268  
Total sales
    248,590       246,982  
                 
Cost of sales
               
Product
    97,150       106,240  
Sevice
    28,174       28,226  
Total cost of sales
    125,324       134,466  
Gross profit
    123,266       112,516  
                 
Operating expenses:
               
Research and development, net
    18,497       16,526  
Selling and marketing
    75,010       72,891  
General and administrative
    20,446       16,912  
Legal settlement, net
    -       766  
                 
Total  Operating expenses
    113,953       107,095  
Operating Income
    9,313       5,421  
                 
Financial expenses, net
    1,464       3,725  
                 
Tax expenses (income)
    852       1,006  
                 
Net Income
  $ 6,997     $ 690  
                 
Basic and diluted net earnings per share
  $ 0.03     $ *) -  
*) Less than $0.01



 
 

 
 
LUMENIS LTD
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Audited)

   
December 31,
   
December 31,
 
   
2012
   
2011
 
          ASSETS
           
Cash and cash equivalents
  $ 27,103     $ 31,023  
Short-term bank deposits
    -       7,475  
Trade receivables
    40,179       41,527  
Other accounts receivable
    10,638       8,293  
Inventories
    35,002       48,284  
                 
Total current Assets
    112,922       136,602  
                 
Severance pay fund
    3,510       3,454  
                 
FINISHED GOODS USED IN OPERATIONS
    3,790       3,638  
                 
PROPERTY AND EQUIPMENT, NET
    7,594       6,194  
                 
GOODWILL
    50,217       50,217  
                 
OTHER ASSETS
    7,090       7,462  
                 
TOTAL ASSETS
  $ 185,123     $ 207,567  
                 
          LIABILITIES AND SHAREHOLDERS'  EQUITY (DEFICIENCY)
               
                 
CURRENT LIABILITIES
               
                 
Current maturities of long term debt
  $ 13,002     $ 17,730  
Trade payables
    15,187       30,159  
Other accounts payable and accrued expenses
    36,371       37,330  
Deferred revenues and advance from customers
    18,007       18,245  
                 
Total current liabilities
    82,567       103,464  
                 
ACCRUED SEVERANCE PAY
    8,956       9,329  
                 
OTHER LONG TERM LIABILITIES
    16,742       14,591  
                 
DEFERRED REVENUES
    7,553       8,070  
                 
LONG TERM DEBT
    69,503       82,714  
                 
TOTAL LIABILITIES
    185,321       218,168  
                 
SHAREHOLDERS' EQUITY (DEFICIENCY)
    (198 )     (10,601 )
                 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)
  $ 185,123     $ 207,567  




 
 

 

LUMENIS LTD
 
Reconciliation of GAAP to Non-GAAP Measures
U.S. dollars in thousands
(Unaudited)

   
Year Ended December 31
 
   
2012
   
2011
 
             
GAAP gross profit
  $ 123,266     $ 112,516  
                 
Stock-based compensation
    127          
One time expenses
    282       104  
Non-GAAP gross profit
  $ 123,675     $ 112,620  
                 
                 
GAAP Operating expenses
  $ 113,953     $ 107,095  
Stock-based compensation:
               
   Research and development, net
    (189 )     (186 )
   Selling and marketing
    (385 )     (249 )
   General and administrative
    (2,584 )     (208 )
Amortization of intangibles:
               
   General and administrative
    -       (397 )
Legal and other:
               
   General and administrative
    (101 )     (1,032 )
Non-GAAP Operating expenses
  $ 110,694     $ 105,023  
                 
GAAP operating income
  $ 9,313     $ 5,421  
Non-GAAP operating income
  $ 12,981     $ 7,597